Life Settlement Fund

A life settlement fund acquires existing life insurance policies from their original owners at a discount, becomes the beneficiary, and collects the death benefit when the insured dies. Investors receive returns based on the gap between the discounted purchase price and the face value of the policy—a legally sanctioned, but ethically contentious, financial instrument that monetizes human mortality.

The life settlement market: why sellers exist

A man aged 75 owns a $1 million life insurance policy. He paid premiums for 30 years. His circumstances change—he needs cash for medical bills, he no longer needs the death benefit for estate planning, or his financial situation deteriorated. Surrendering the policy to the insurer yields $150,000 (the cash surrender value). A life settlement dealer offers him $320,000. The difference—$170,000—is still far less than the $1 million face value, but far more than surrender value. He takes the deal.

A life settlement fund enters here. The fund purchases the policy from the seller (or from a secondary-market dealer), takes over premium payments, names itself as the beneficiary, and holds the policy until the insured dies. At death, the fund collects the full $1 million face value. After deducting the $320,000 purchase price, the subsequent premiums (say $800,000 total over 8 years), and operational costs, the fund might net a $100,000+ profit on a $1.12 million investment—a 6–8% annual return if spread over 8 years.

This is not insurance in the traditional sense. The seller is no longer the insured person; the original life insurance protection has been severed from the human relationship. It is a financial contract pure and simple: the fund bets that it will collect more than it pays out.

How life settlement pricing works: actuarial math

A 75-year-old man with a $1 million policy might have a 40–50% probability of living another 10 years (depending on health). An insurer’s mortality tables estimate his life expectancy. A life settlement fund uses the same tables to estimate the present value of the death benefit.

If the insured has a 50% chance of dying within 8 years, the fund assigns a high probability to receiving the benefit soon. If he has a 15% chance of dying within 3 years, the fund is taking a long-duration bet. The fund discounts the expected death benefit by:

• Probability of death in each future year (from mortality tables)
• Discount rate (typically 10–15%, reflecting the risk and illiquidity)
• Ongoing premium costs (the fund must pay insurance premiums for as long as the insured lives)

A simplified example: a $1 million benefit with 60% probability of payment in 5 years, 10% cost of capital, and $50,000 in total future premiums yields an expected present value of roughly $400,000 to $500,000. A fund buying the policy at $320,000 would be profitable if mortality assumptions are accurate.

The mathematics are complex. Actuarial firms specialize in life expectancy assessment, using medical records, age, gender, health history, and lifestyle. Small errors in mortality projection—if the insured lives 2–3 years longer than expected—compress returns significantly. If the insured dies ahead of schedule, returns spike.

Types of life settlements and viatical settlements

A life settlement historically involves the sale of a policy by an elderly person in normal health, expecting to live 5–15 years. A viatical settlement involves a person with a diagnosed terminal illness (often HIV/AIDS, though the distinction has blurred as treatment improves). Viatical settlements typically offer much higher discounts because the insured’s life expectancy is measured in months or a few years.

Viatical settlements emerged in the 1990s as a way for terminally ill people to access their insurance benefits while alive. They were particularly common during the AIDS crisis. As medical advances extended life, viatical settlements became less common and more regulatory scrutiny emerged. Life settlements, applicable to healthier but older individuals, became the larger market.

Both structures involve identical risks from an investor’s perspective: the insured might live longer than expected, reducing or eliminating returns.

The longevity risk problem

The single greatest risk in life settlement funds is longevity risk: the insured lives substantially longer than mortality tables predicted. Medical advances, improved treatments, or simply underestimating an individual’s health can shift life expectancy forward by years.

If a fund buys a policy expecting the insured to die in 6 years but he lives 12 years, the fund must pay an extra 6 years of premiums—often $50,000–$150,000 per year per policy. These costs erode the capital return. In extreme cases, cumulative premiums can exceed the face value, turning a profitable investment into a loss.

Funds manage this risk by:

• Diversifying across many policies, so a few long-lived outliers are balanced by those who die sooner
• Conservative underwriting, selecting insureds with clear health impairments or advanced age
• Regularly updating life expectancy, checking current health, and adjusting reserve assumptions

A well-run fund with 100+ policies can absorb variance. A small fund with 10 policies is vulnerable to a few long-lived individuals.

Policy lapse and insured fraud

A second risk is policy lapse. If the insured stops paying premiums and the policy lapses, the fund loses the death benefit. Funds mitigate this by paying premiums on behalf of the insured—the fund essentially has a financial interest in keeping the person alive (a situation unique to life settlements, and ethically unusual).

Insured fraud is a third, smaller risk. A seller might conceal serious health conditions at the time of sale, inflating the purchase price. Or, in historical cases, organized crime purchased policies on strangers and then had them killed—a practice called “murder for insurance.” Regulatory frameworks now require vetting and mandate that the seller have an “insurable interest” (a legitimate financial or familial reason to know the insured’s health).

Ethical and social considerations

Life settlements exist in a moral gray zone. Proponents argue they provide liquidity to elderly people who need cash. Opponents argue they commodify human mortality and create incentives—however remote—for beneficiaries to wish the insured dead. The practice is regulated in most U.S. states and many countries to prevent abuse, but regulation varies widely.

Funds are required to disclose that they are investing in human death and to comply with state laws governing settlement purchases. Some jurisdictions prohibit viatical settlements or impose strict underwriting rules. The financial crisis of 2008–2009 saw some life settlement funds collapse when longevity assumptions proved too optimistic, burning investors.

Fund structure and tax treatment

Many life settlement funds are structured as hedge funds or private funds, closed to retail investors. Some have been offered as mutual funds or interval funds. Shares are typically illiquid, redeemable only quarterly or annually.

Tax treatment is complex. Death benefits from life insurance policies are normally tax-free to the original beneficiary. However, when a policy is sold, and a third party becomes the beneficiary, the death benefit may be partially taxable as ordinary income. The portion equal to premiums paid by the fund may be tax-free, but any gain above that could be taxed. Rules vary by jurisdiction.

Returns, duration, and realism

Funds advertise expected returns of 7–15% annually. Historical data is sparse because the market is opaque and many funds are private. Those that have reported actual returns have been mixed: some delivered promised returns, others underperformed due to longer-than-expected lifespans or operational issues.

The duration of a fund matters significantly. A fund holding mostly policies on 80-year-olds might distribute most capital within 8–10 years. A fund holding policies on 60-year-olds might lock capital for 20+ years. Investors seeking liquid returns may find life settlements unsuitable.

The market remains small relative to mainstream investments, with estimated assets under management in the low billions. Regulatory scrutiny and media attention around ethical concerns have constrained growth.

See also